Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, Luciferase PPI stable cell lines, kinase assay kits, peptide substrate, mobility shifty assay, and lipid kinase panels. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection assays. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Sumitomo Pharma, Gilead Sciences. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.
तुलना करने के लिए मीट्रिक्स | 4572 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4572पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −3.8x | −0.9x | −0.6x | |
PEG अनुपात | −0.16 | −0.03 | 0.00 | |
क़ीमत/बुक | 2.2x | 2.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 4.1x | 2.4x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 45.4% | 52.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 18.2% | 8.4% | अनलॉक करें |